Vyne Therapeutics Inc • VYNE

Capital at risk.

About Vyne Therapeutics Inc
Ticker
info
VYNE
Trading on
info
NASDAQ
ISIN
info
US92941V2097
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
David T. Domzalski
Headquarters
info
685 Route 202/206 N, Bridgewater, NJ, United States, 08807
Employees
info
13
Website
info
https://vynetherapeutics.com
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Metrics
BasicAdvanced
Market cap
info
$8.8M
P/E ratio
info
-
EPS
info
-$0.90
Dividend Yield
info
0.00%
Beta
info
1.91
Forward P/E ratio
info
0
EBIDTA
info
$-43.6M
Ex dividend date
info
-
Price & volume
Market cap
info
$8.8M
Average daily volume
info
2.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
18.53
Price to book
info
0.21
Earnings
EPS
info
-$0.90
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-43.6M
Revenues (TTM)
info
$0.5M
Revenues per share (TTM)
info
$0.01
Technicals
Beta
info
1.91
52-week High
info
$4.30
52-week Low
info
$0.28
50-day moving average
info
$0.34
200-day moving average
info
$1.24
Short ratio
info
0.26
Short %
info
3.15%
Management effectiveness
ROE (TTM)
info
-67.73%
ROA (TTM)
info
-40.54%
Profit margin
info
0.00%
Gross profit margin
info
$0.5M
Operating margin
info
-10,930.43%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-65.20%
Share stats
Outstanding Shares
info
25.5M
Float
info
23.3M
Insiders %
info
5.31%
Institutions %
info
34.54%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 4 analysts.

Average price target

info
$4.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.29
-$0.23
-26.09%
Q3 • 24Missed
-$0.28
-$0.30
6.96%
Q4 • 24Beat
-$0.20
-$0.29
31.03%
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.2M
$-8.6M
-4,262.87%
Q1 • 25
$0.1M
$-5.8M
-8,340.58%
Q2 • 25
-65.84%
-33.17%
95.66%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$56.4M
$12.3M
21.78%
Q1 • 25
$44.7M
$5.8M
13.05%
Q2 • 25
-20.75%
-52.52%
-40.09%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-11.5M
$19.8M
$-0.1M
$-11.5M
Q1 • 25
$-10.8M
$4.7M
$-0M
$-10.8M
Q2 • 25
-5.74%
-76.43%
-60.92%
-5.74%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Vyne Therapeutics Inc share?
Collapse

Vyne Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Vyne Therapeutics Inc have?
Collapse

Vyne Therapeutics Inc currently has 25.5M shares.

Does Vyne Therapeutics Inc pay dividends?
Collapse

No, Vyne Therapeutics Inc doesn't pay dividends.

What is Vyne Therapeutics Inc 52 week high?
Collapse

Vyne Therapeutics Inc 52 week high is $4.30.

What is Vyne Therapeutics Inc 52 week low?
Collapse

Vyne Therapeutics Inc 52 week low is $0.28.

What is the 200-day moving average of Vyne Therapeutics Inc?
Collapse

Vyne Therapeutics Inc 200-day moving average is $1.24.

Who is Vyne Therapeutics Inc CEO?
Collapse

The CEO of Vyne Therapeutics Inc is David T. Domzalski.

How many employees Vyne Therapeutics Inc has?
Collapse

Vyne Therapeutics Inc has 13 employees.

What is the market cap of Vyne Therapeutics Inc?
Collapse

The market cap of Vyne Therapeutics Inc is $8.8M.

What is the P/E of Vyne Therapeutics Inc?
Collapse

The current P/E of Vyne Therapeutics Inc is null.

What is the EPS of Vyne Therapeutics Inc?
Collapse

The EPS of Vyne Therapeutics Inc is -$0.90.

What is the PEG Ratio of Vyne Therapeutics Inc?
Collapse

The PEG Ratio of Vyne Therapeutics Inc is null.

What do analysts say about Vyne Therapeutics Inc?
Collapse

According to the analysts Vyne Therapeutics Inc is considered a buy.